1998
Reversal of Established Rat Crescentic Glomerulonephritis by Blockade of Macrophage Migration Inhibitory Factor (MIF): Potential Role of MIF in Regulating Glucocorticoid Production
Yang N, Nikolic-Paterson D, Ng Y, Mu W, Metz C, Bacher M, Meinhardt A, Bucala R, Atkins R, Lan H. Reversal of Established Rat Crescentic Glomerulonephritis by Blockade of Macrophage Migration Inhibitory Factor (MIF): Potential Role of MIF in Regulating Glucocorticoid Production. Molecular Medicine 1998, 4: 413-424. PMID: 10780884, PMCID: PMC2230272, DOI: 10.1007/bf03401748.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMigration inhibitory factorCrescentic glomerulonephritisDay 7Ab treatmentRenal functionControl AbInhibitory factorPotent pro-inflammatory cytokineEndogenous glucocorticoid levelsIsotype control AbSevere renal injuryNormal renal functionCellular immune responsesPro-inflammatory cytokinesReversal of diseaseSerum corticosterone levelsExperimental crescentic glomerulonephritisInterleukin-1 productionRat crescentic glomerulonephritisCrescentic diseaseProgressive glomerulonephritisRenal injuryGBM glomerulonephritisLeukocyte infiltration
1995
Advanced glycosylation end products in diabetic renal and vascular disease
Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal Of Kidney Diseases 1995, 26: 875-888. PMID: 7503061, DOI: 10.1016/0272-6386(95)90051-9.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsPhase II/III clinical trialsNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesRenal functionVascular complicationsDiabetic nephropathyGlomerular sclerosisGlucose-derived Amadori productsEtiologic roleVascular diseaseClinical trialsMatrix protein synthesisTherapeutic modalitiesVascular permeabilityAdvanced glycosylationLipoprotein depositionEnd productsTissue toxicityNitric oxidePharmacologic inhibitorsToxicityProtein synthesisAdvanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts